BioVie Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
BioVie Inc. (BIVI) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of -$8.57 million for the 12-month period ending 2026-06-30, per its 10-K filed 2026-08-13.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-08-13
- BioVie Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-09-30 was $7.43M.
- BioVie Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-09-30 was -$3.82M, a 317.84% decline year-over-year.
- BioVie Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-09-30 was $1.75M, a 32.27% decline year-over-year.
- BioVie Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2022-09-30 was $2.59M, a 83.79% decline year-over-year.
- BioVie Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2026 was -$8.57M.
- BioVie Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was -$6.30M.
- BioVie Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was $819.17K, a 94.20% decline from fiscal 2022.
- BioVie Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was $14.13M, a 215.79% increase from fiscal 2021.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$8.57M 10-K · filed 2026-08-13 | |||
| 2026-03-31 | -$4.45M S-1/A · filed 2026-08-06 | |||
| 2025-12-31 | $3.00M 10-Q · filed 2026-02-06 | |||
| 2025-09-30 | $7.43M 10-Q · filed 2025-11-10 | |||
| 2025-06-30 | -$6.30M 10-K · filed 2026-08-13 | |||
| 2025-03-31 | -$691.78K S-1/A · filed 2026-08-06 | |||
| 2024-12-31 | $561.72K 10-Q · filed 2026-02-06 | |||
| 2024-09-30 | -$3.82M 10-Q · filed 2025-11-10 | |||
| 2024-06-30 | $4.38M S-1/A · filed 2026-08-06 | |||
| 2024-03-31 | $10.89M 10-Q · filed 2025-05-12 | |||
| 2023-12-31 | $765.82K 10-Q · filed 2025-02-11 | |||
| 2023-09-30 | $1.75M 10-Q · filed 2024-11-13 | |||
| 2023-06-30 | $819.17K 10-K · filed 2024-09-30 | |||
| 2023-03-31 | $12.63M 10-Q · filed 2024-05-14 | |||
| 2022-12-31 | $27.11M 10-Q · filed 2024-02-13 | |||
| 2022-09-30 | $2.59M 10-Q · filed 2023-11-08 | |||
| 2022-06-30 | $14.13M 10-K · filed 2023-08-16 | |||
| 2022-03-31 | $20.00M 10-Q · filed 2023-05-12 | |||
| 2021-12-31 | $25.88M 10-Q · filed 2023-02-10 | |||
| 2021-09-30 | $15.98M 10-Q · filed 2022-11-04 | |||
| 2021-06-30 | $4.47M 10-K · filed 2022-09-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |